FDA grants fast track status to Novo Nordisk’s ATTR-CM drug

DUBLIN - The U.S. Food and Drug Administration has granted Fast Track Designation to coramitug, an investigational antibody for treating ATTR amyloidosis with cardiomyopathy, Prothena Corporation plc (NASDAQ:PRTA) announced today.